Evidence map›Paper›PMID 29404445›Full record

ArticleHepatology communications2017

Periostin promotes malignant potential by induction of epithelial-mesenchymal transition in intrahepatic cholangiocarcinoma.

Masaaki Mino, Keishi Kanno, Kousuke Okimoto, Akiko Sugiyama, Nobusuke Kishikawa, Tomoki Kobayashi, Junya Ono, Kenji Izuhara, Tsuyoshi Kobayashi, Toshikazu Ohigashi and 2 more

Open access · goldAbstract read
In one paragraph

Article in Hepatology communications, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 1 pooled it
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 1 synthesis or guideline pooled it, 14 citations in OpenAlex.

  1. Biomarkers of tumor invasiveness in proteomics (Review).International journal of oncology · 2020
    Pooled it
  2. Review
  3. Cholangiocarcinoma 2026: status quo, unmet needs and priorities.Nature reviews. Gastroenterology & hepatology · 2026
    Review
  4. Article
  5. Article
  6. Article
  7. The role of periostin in cardiac fibrosis.Heart failure reviews · 2024
    Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Masaaki MinoDepartment of General Internal Medicine Hiroshima University Hospital Hiroshima Japan.
Keishi KannoDepartment of General Internal Medicine Hiroshima University Hospital Hiroshima Japan.
Kousuke OkimotoDepartment of General Internal Medicine Hiroshima University Hospital Hiroshima Japan.
Akiko SugiyamaDepartment of General Internal Medicine Hiroshima University Hospital Hiroshima Japan.
Nobusuke KishikawaDepartment of General Internal Medicine Hiroshima University Hospital Hiroshima Japan.
Tomoki KobayashiDepartment of General Internal Medicine Hiroshima University Hospital Hiroshima Japan.
Junya OnoCentral Institute Shino-Test Corporation Kanagawa Japan.
Kenji IzuharaDivision of Medical Biochemistry, Department of Laboratory Medicine Saga Medical School Saga Japan.
Tsuyoshi KobayashiDepartment of Gastroenterological and Transplant Surgery Hiroshima University Hospital Hiroshima Japan.
Toshikazu OhigashiDepartment of Pharmaceutical Services Hiroshima University Hospital Hiroshima Japan.
Hideki OhdanDepartment of Gastroenterological and Transplant Surgery Hiroshima University Hospital Hiroshima Japan.
Susumu TazumaDepartment of General Internal Medicine Hiroshima University Hospital Hiroshima Japan.
Hiroshima University Hospital · JPSaga Medical School Hospital · JPShino-Test Corporation

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Periostin, a secreted matricellular protein, has been reported to induce epithelial-mesenchymal transition (EMT), which increases motility and invasiveness in various epithelial cancer cells. Periostin is also overexpressed in intrahepatic cholangiocarcinoma (ICC) and suggested to be a biomarker for tumor progression and poor prognosis; however, its functional role in ICC is not fully understood. Here, we investigated whether periostin influences malignant potential through the induction of EMT in ICC. Analyses of surgical resected ICC specimens revealed that the gene expression of periostin was significantly higher in ICC tumors than in adjacent nontumor liver tissues and was closely correlated with the expression of mesenchymal markers, including N-cadherin, vimentin, and fibronectin. However, the expression level of periostin varied in each case. Consistently, the expression of periostin in HuH28 (an undifferentiated ICC cell) was markedly higher than in HuCCT-1 (a moderately differentiated ICC cell). In addition, high-level secretion of periostin into culture media was observed in HuH28 but not in HuCCT-1. To identify the biological significance of periostin in EMT, gene silencing of periostin by small interfering RNA was performed in HuH28 cells. Periostin knockdown in HuH28 cells significantly down-regulated mesenchymal markers and up-regulated epithelial markers, suggesting the reversal of EMT, namely mesenchymal-epithelial transition. Along with these changes, cell proliferation was significantly suppressed by 52%. In addition, cell migration and invasion were significantly suppressed by 62% and 61%, respectively, with reduced gene expression of matrix metalloproteinase 2. Interestingly, chemosensitivity to gemcitabine was also significantly improved by periostin depletion.

Identifiers

PMID29404445
PMCPMC5721406
OpenAlexW2606071412

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.